Medical City Fort Worth of Fort Worth Research

Clinical Trials: Partnering with You Today to Benefit Medicine Tomorrow

The Medical City Fort Worth Research team is dedicated to helping find prevention therapies and treatments for diseases and illnesses. We participate in a number of clinical trials and scientific studies that test new drugs and devices. Our research is focused mainly on cardiovascular, electrophysiology and neurological medicine.

The Medical City Fort Worth Research Office also collaborates with the UNT Health Science Center master of science program in clinical management. As part of their curriculum, students in this program have a six-month practicum with the Medical City Fort Worth Research team, culminating in a scientific thesis. A Medical City Fort Worth representative is part of the faculty advisory committee for the student.

By taking part in a clinical trial, you can:

  • Play a more active role in your own health care
  • Help others by contributing to medical research

To see if you qualify for enrollment in one of our clinical trials, call (817) 347-6058 .

Active Clinic Trials at Medical City Fort Worth

Medical City Fort Worth is currently seeking volunteers for these studies:

  • COBRA - Participants will help study doctors learn whether the investigational COBRA PzF coronary (heart) stent works for opening up the blocked or narrowed blood vessels in the hearts of patients with coronary artery disease (CAD.
  • Dance - Studies whether dexamethasone, an FDA-approved anti-inflammatory drug, can be delivered safely into the tissue around the blood vessel at the time of angioplasty or atherectomy and prevent re-narrowing of the blood vessel.
  • Odyssey - The study hopes to prevent future heart events by using an injectable investigational drug to lower bad cholesterol (LDL) in people with a history of heart disease. This medication is used with statins. The study is being conducted worldwide and has passed through early phases of clinical trials.
  • Platinum - Gathers information (i.e. medical history, demographics) from women and minorities with coronary artery disease who have been treated with the Promus PREMIER coronary (heart) stent. This is an observational study and no investigational medications or medical devices will be administered as part of this study.
  • WRAP-IT - The Worldwide Randomized Antibiotic EnveloPe Infection PrevenTion Clinical Study evaluates an antibacterial envelope in cardiovascular implantable electronic device (CIED) patients who are at risk for infections. A mesh envelope holds an implantable cardiac device and is designed to stabilize the device after implantation while releasing antimicrobial agents, minocycline and rifampin. The envelope is fully absorbed by the body approximately nine weeks after implantation.

Enrollment is Closed for these Active Clinical Trials

  • CANOPY study - Purpose is to continue evaluating the safety and effectiveness of the RX Acculink Carotid Stent System.
  • SuperNova - Studies whether the investigational INNOVA stent works for opening up the blocked or narrowed blood vessels in the upper legs of patients with peripheral artery disease (PAD).

Neuroscience Research at Medical City Fort Worth

The research office at Medical City Fort Worth has successfully collaborated with the Texas Stroke Institute (TSI) to implement neuroscience research at Medical City Fort Worth.

A product of this is the FIRST study, with principal investigator Dr. Vallabh Janardhan of TSI. This is a prospective, multi-center, single-arm natural history study of the natural evolution of ischemic stroke. Enrolled patients presented in the hospital with a large vessel occlusion in the brain within eight hours of symptom onset, with a baseline NIHSS score equal to or more than 10. The cohort had to be ineligible or refractory to lytic therapy and eligible for, but untreated by intra-arterial therapy.

Dr. Janardhan summarized the importance of the findings of this study: “Our initial results show that blocked blood vessels that result in ‘brain attacks’ can have devastating outcomes, with close to 80 percent of patients either dying or becoming severely disabled, if intra-arterial treatment options are not available within the required time frame. With the addition of FIRST data to the growing research portfolio on intra-arterial therapy, the scientific community will benefit from the ability to measure future device trials against a viable control population.”

Research Office Supervisor: Dr. Rubina Muzina
Principal Research Investigator: Dr. Amir Malik
Sub-investigators: Dr. Farhan Ali, Dr. Giri Mundluru, Dr. Ashesh Parikh and physicians in Plaza’s cardiology fellowship program.

“The only way of discovering the limits of the possible is to venture a little way past them into the impossible” – Arthur (Charles) Clarke